The ETS2 antibody targets the ETS2 protein, a member of the ETS (E26 transformation-specific) family of transcription factors. ETS2 is encoded by the *ETS2* gene and plays a critical role in regulating gene expression involved in cell proliferation, differentiation, apoptosis, and oncogenesis. It binds to DNA via a conserved ETS domain, recognizing GGAA/T-rich sequences in promoter or enhancer regions of target genes. ETS2 is implicated in various biological processes, including embryonic development, immune response, and tissue remodeling, and its dysregulation has been linked to cancers (e.g., prostate, breast, colorectal) and inflammatory diseases.
Antibodies against ETS2 are widely used in research to study its expression, localization, and function. They enable techniques such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and chromatin immunoprecipitation (ChIP), helping to elucidate ETS2’s role in signaling pathways (e.g., MAPK/ERK) and its interaction with co-regulators. Commercial ETS2 antibodies are typically validated for specificity using knockout controls or siRNA knockdown. Researchers must consider factors like antibody clonality (monoclonal vs. polyclonal), host species, and epitope regions when selecting reagents. Despite its importance, cross-reactivity with homologous ETS family members (e.g., ETS1) remains a potential challenge, necessitating careful experimental design. Overall, ETS2 antibodies are vital tools for exploring its contributions to normal physiology and disease pathology.